Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells

Federica Barbieri, Angela Alama, Bruno Tasso, Vito Boido, Cristina Bruzzo, Fabio Sparatore

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The development of multidrug-resistance (MDR) in neoplastic cells is often responsible for the therapy failure and poor outcome of a number of human cancers. MDR may be associated with the expression of the multidrug transporter glycoprotein p170, encoded by the MDR1 gene, which acts as an ATP-dependent efflux pump by reducing the intracellular accumulation of some cytotoxic agents. A variety of iminodibenzyl and phenothiazine derivatives, characterized by the presence of a bicyclic, strongly basic, and highly lipophilic quinolizidine nucleus, were synthesized to investigate their ability to modulate the MDR phenotype. A set of 10 of them (named 1-10), bearing quinolizidine moiety linked through different connecting chains, were tested as chemoresistance- reversing agents on doxorubicin-resistant ovarian cancer cells (A2780-DX3). A 51-fold resistance to doxorubicin was reported in the A2780-DX3 compared to the parental sensitive A2780 WT with mean IC50 values of 0.02 and 1.02 μM, respectively. Moreover, overexpression of the glycoprotein p170 in the resistant cell line was detected by Western blot analysis. By cytotoxicity assays and time-course experiments, different treatment schedules with resistance modulators (including clomipramine as reference drug) and doxorubicin were taken into account. The 16 h exposure of cells to 1 μM of modulator before doxorubicin demonstrated to be superior in sensitizing the resistant cell line. In particular, compounds 8, 7, 10, and 4 increasingly potentiated doxorubicin cytotoxicity, up to 5.6-fold in A2780-DX3 cells. The present results suggest promising indications for further development of these compounds as chemosensitizing drugs.

Original languageEnglish
Pages (from-to)413-420
Number of pages8
JournalInvestigational New Drugs
Volume21
Issue number4
DOIs
Publication statusPublished - Nov 2003

Fingerprint

Multiple Drug Resistance
Ovarian Neoplasms
Doxorubicin
Quinolizidines
Glycoproteins
Clomipramine
Cell Line
Cytotoxins
Pharmaceutical Preparations
Inhibitory Concentration 50
Appointments and Schedules
Adenosine Triphosphate
Western Blotting
dibenzylamine
phenothiazine
Phenotype
Genes
Neoplasms

Keywords

  • Chemosensitizers
  • Cytotoxicity
  • Iminodibenzyl derivatives
  • Ovarian cancer cells
  • Phenothiazine derivatives
  • Quinolizidinyl derivatives

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells. / Barbieri, Federica; Alama, Angela; Tasso, Bruno; Boido, Vito; Bruzzo, Cristina; Sparatore, Fabio.

In: Investigational New Drugs, Vol. 21, No. 4, 11.2003, p. 413-420.

Research output: Contribution to journalArticle

Barbieri, Federica ; Alama, Angela ; Tasso, Bruno ; Boido, Vito ; Bruzzo, Cristina ; Sparatore, Fabio. / Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells. In: Investigational New Drugs. 2003 ; Vol. 21, No. 4. pp. 413-420.
@article{e50613d98da54ad3a8c7f9f00f213975,
title = "Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells",
abstract = "The development of multidrug-resistance (MDR) in neoplastic cells is often responsible for the therapy failure and poor outcome of a number of human cancers. MDR may be associated with the expression of the multidrug transporter glycoprotein p170, encoded by the MDR1 gene, which acts as an ATP-dependent efflux pump by reducing the intracellular accumulation of some cytotoxic agents. A variety of iminodibenzyl and phenothiazine derivatives, characterized by the presence of a bicyclic, strongly basic, and highly lipophilic quinolizidine nucleus, were synthesized to investigate their ability to modulate the MDR phenotype. A set of 10 of them (named 1-10), bearing quinolizidine moiety linked through different connecting chains, were tested as chemoresistance- reversing agents on doxorubicin-resistant ovarian cancer cells (A2780-DX3). A 51-fold resistance to doxorubicin was reported in the A2780-DX3 compared to the parental sensitive A2780 WT with mean IC50 values of 0.02 and 1.02 μM, respectively. Moreover, overexpression of the glycoprotein p170 in the resistant cell line was detected by Western blot analysis. By cytotoxicity assays and time-course experiments, different treatment schedules with resistance modulators (including clomipramine as reference drug) and doxorubicin were taken into account. The 16 h exposure of cells to 1 μM of modulator before doxorubicin demonstrated to be superior in sensitizing the resistant cell line. In particular, compounds 8, 7, 10, and 4 increasingly potentiated doxorubicin cytotoxicity, up to 5.6-fold in A2780-DX3 cells. The present results suggest promising indications for further development of these compounds as chemosensitizing drugs.",
keywords = "Chemosensitizers, Cytotoxicity, Iminodibenzyl derivatives, Ovarian cancer cells, Phenothiazine derivatives, Quinolizidinyl derivatives",
author = "Federica Barbieri and Angela Alama and Bruno Tasso and Vito Boido and Cristina Bruzzo and Fabio Sparatore",
year = "2003",
month = "11",
doi = "10.1023/A:1026295017158",
language = "English",
volume = "21",
pages = "413--420",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells

AU - Barbieri, Federica

AU - Alama, Angela

AU - Tasso, Bruno

AU - Boido, Vito

AU - Bruzzo, Cristina

AU - Sparatore, Fabio

PY - 2003/11

Y1 - 2003/11

N2 - The development of multidrug-resistance (MDR) in neoplastic cells is often responsible for the therapy failure and poor outcome of a number of human cancers. MDR may be associated with the expression of the multidrug transporter glycoprotein p170, encoded by the MDR1 gene, which acts as an ATP-dependent efflux pump by reducing the intracellular accumulation of some cytotoxic agents. A variety of iminodibenzyl and phenothiazine derivatives, characterized by the presence of a bicyclic, strongly basic, and highly lipophilic quinolizidine nucleus, were synthesized to investigate their ability to modulate the MDR phenotype. A set of 10 of them (named 1-10), bearing quinolizidine moiety linked through different connecting chains, were tested as chemoresistance- reversing agents on doxorubicin-resistant ovarian cancer cells (A2780-DX3). A 51-fold resistance to doxorubicin was reported in the A2780-DX3 compared to the parental sensitive A2780 WT with mean IC50 values of 0.02 and 1.02 μM, respectively. Moreover, overexpression of the glycoprotein p170 in the resistant cell line was detected by Western blot analysis. By cytotoxicity assays and time-course experiments, different treatment schedules with resistance modulators (including clomipramine as reference drug) and doxorubicin were taken into account. The 16 h exposure of cells to 1 μM of modulator before doxorubicin demonstrated to be superior in sensitizing the resistant cell line. In particular, compounds 8, 7, 10, and 4 increasingly potentiated doxorubicin cytotoxicity, up to 5.6-fold in A2780-DX3 cells. The present results suggest promising indications for further development of these compounds as chemosensitizing drugs.

AB - The development of multidrug-resistance (MDR) in neoplastic cells is often responsible for the therapy failure and poor outcome of a number of human cancers. MDR may be associated with the expression of the multidrug transporter glycoprotein p170, encoded by the MDR1 gene, which acts as an ATP-dependent efflux pump by reducing the intracellular accumulation of some cytotoxic agents. A variety of iminodibenzyl and phenothiazine derivatives, characterized by the presence of a bicyclic, strongly basic, and highly lipophilic quinolizidine nucleus, were synthesized to investigate their ability to modulate the MDR phenotype. A set of 10 of them (named 1-10), bearing quinolizidine moiety linked through different connecting chains, were tested as chemoresistance- reversing agents on doxorubicin-resistant ovarian cancer cells (A2780-DX3). A 51-fold resistance to doxorubicin was reported in the A2780-DX3 compared to the parental sensitive A2780 WT with mean IC50 values of 0.02 and 1.02 μM, respectively. Moreover, overexpression of the glycoprotein p170 in the resistant cell line was detected by Western blot analysis. By cytotoxicity assays and time-course experiments, different treatment schedules with resistance modulators (including clomipramine as reference drug) and doxorubicin were taken into account. The 16 h exposure of cells to 1 μM of modulator before doxorubicin demonstrated to be superior in sensitizing the resistant cell line. In particular, compounds 8, 7, 10, and 4 increasingly potentiated doxorubicin cytotoxicity, up to 5.6-fold in A2780-DX3 cells. The present results suggest promising indications for further development of these compounds as chemosensitizing drugs.

KW - Chemosensitizers

KW - Cytotoxicity

KW - Iminodibenzyl derivatives

KW - Ovarian cancer cells

KW - Phenothiazine derivatives

KW - Quinolizidinyl derivatives

UR - http://www.scopus.com/inward/record.url?scp=1642452917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642452917&partnerID=8YFLogxK

U2 - 10.1023/A:1026295017158

DO - 10.1023/A:1026295017158

M3 - Article

C2 - 14586208

AN - SCOPUS:1642452917

VL - 21

SP - 413

EP - 420

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -